RT Journal Article SR Electronic T1 Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-Microspheres Used in Preradioembolization Dosimetry: Influence on the Liver–Lung Shunt JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 925 OP 927 DO 10.2967/jnumed.115.169987 VO 57 IS 6 A1 Grosser, Oliver S. A1 Ruf, Juri A1 Kupitz, Dennis A1 Pethe, Annette A1 Ulrich, Gerhard A1 Genseke, Philipp A1 Mohnike, Konrad A1 Pech, Maciej A1 Richter, Wolf S. A1 Ricke, Jens A1 Amthauer, Holger YR 2016 UL http://jnm.snmjournals.org/content/57/6/925.abstract AB Perfusion scintigraphy using 99mTc-labeled albumin aggregates is mandatory before hepatic radioembolization with 90Y-microspheres. As part of a prospective trial, the intrahepatic and intrapulmonary stability of 2 albumin compounds, 99mTc-MAA (macroaggregated serum albumin [MAA]) and 99mTc-HSA (human serum albumin [HSA]), was assessed. Methods: In 24 patients with metastatic colorectal cancer, biodistribution (liver, lung) and liver–lung shunt (LLS) of both tracers (12 patients each) were assessed by sequential planar scintigraphy (1, 5, and 24 h after injection). Results: Liver uptake of both albumin compounds decreased differently. Although initial LLSs at 1 h after injection were similar in both groups, MAA-LLS increased significantly from 1 (3.9%) to 5 h (7.7%) and 24 h (9.9%) after injection, respectively. HSA-LLS did not change significantly (1 to 5 h), indicating a steady state of pulmonary and intrahepatic degradation. Conclusion: Compared with 99mTc-MAA-microspheres, 99mTc-HSA-microspheres are likely more resistant to degradation over time, allowing a reliable LLS determination even at later time points.